<DOC>
	<DOCNO>NCT00911079</DOCNO>
	<brief_summary>RATIONALE : Hyperthermia therapy kill tumor cell heat several degree normal body temperature . Ultrasound energy may able kill tumor cell heat tumor cell without affect surround tissue . Implant radiation therapy use radioactive material place directly near tumor kill tumor cell . Giving ultrasound hyperthermia therapy implant radiation therapy may kill tumor cell . PURPOSE : This clinical trial study ultrasound hyperthermia therapy see well work implant radiation therapy treat patient Stage III/IV cancer cervix prostate cancer rise prostate specific antigen ( PSA ) prior local therapy .</brief_summary>
	<brief_title>Pilot Study Catheter-based Ultrasound Hyperthermia System</brief_title>
	<detailed_description>OUTLINE : Patients undergo standard high-dose rate ( HDR ) brachytherapy . Approximately 2 hour brachytherapy , patient undergo catheter-based ultrasound hyperthermia therapy 60 minute . Treatment HDR brachytherapy hyperthermia therapy repeat within 1-3 week . Patients may undergo 2 additional standard HDR brachytherapy session . After completion study therapy , patient follow 1 3 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<criteria>Patients give HDR brachytherapy treatment solid tumor follow : Cervical cancer Stage III IV OR Prostate cancer ( rise prostate specific antigen prior local therapy ) Age â‰¥18 year Eligible brachytherapy determine per clinical standard care . Ability give write informed consent willingness comply requirement protocol Patients candidate HDR brachytherapy Any condition compromise compliance objective procedure protocol , judge principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Stage III , IV cervical cancer</keyword>
	<keyword>Rising prostate specific antigen ( PSA ) local therapy</keyword>
</DOC>